InMed Pharmaceuticals Inc Cash Flow Conversion Efficiency
InMed Pharmaceuticals Inc cash flow conversion efficiency. Based on the latest financial reports, InMed Pharmaceuticals Inc (INM) has a cash flow conversion efficiency ratio of -6.543x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-7.03 Billion) by net assets ($1.08 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of InMed Pharmaceuticals Inc (2001–2026)
Cash flow conversion efficiency of InMed Pharmaceuticals Inc from 2001 to 2026. This chart illustrates how InMed Pharmaceuticals Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View today's stock price for InMed Pharmaceuticals Inc for real-time trading data and today's change.
InMed Pharmaceuticals Inc Cash Flow Conversion Ratio Explained
InMed Pharmaceuticals Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
InMed Pharmaceuticals Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of InMed Pharmaceuticals Inc ranked by their cash flow conversion efficiency. Also see InMed Pharmaceuticals Inc stock valuation for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Raize Servicos de Gestao SA
LS:MLRZE
|
N/A |
|
Mathios Refractories S.A.
AT:MATHIO
|
0.009x |
|
Tigi Ltd
TA:TIGI
|
-1.090x |
|
Prasidha Aneka Niaga Tbk
JK:PSDN
|
-0.096x |
|
Visgeneer
TWO:4197
|
-0.062x |
|
Fountain
BR:FOU
|
0.445x |
|
Beeio Honey Ltd
TA:BHNY
|
-0.162x |
|
JPMorgan Euro Small Companies Trust Plc
LSE:JEDT
|
0.026x |
Annual Cash Flow Conversion Efficiency for InMed Pharmaceuticals Inc (2001–2026)
The table below shows the annual cash flow conversion efficiency of InMed Pharmaceuticals Inc from 2001 to 2026. Review free cash flow generation of InMed Pharmaceuticals Inc to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2026-06-30 | $1.08 Billion | $-8.64 Billion | -8.040x | -1794.80% |
| 2025-06-30 | $18.30 Million | $-7.77 Million | -0.424x | +23.52% |
| 2024-06-30 | $12.59 Million | $-6.99 Million | -0.555x | -22.01% |
| 2023-06-30 | $16.02 Million | $-7.28 Million | -0.455x | +65.89% |
| 2022-06-30 | $11.69 Million | $-15.58 Million | -1.333x | -24.22% |
| 2021-06-30 | $9.12 Million | $-9.79 Million | -1.073x | +14.46% |
| 2020-06-30 | $5.88 Million | $-7.37 Million | -1.255x | -98.63% |
| 2019-06-30 | $13.88 Million | $-8.77 Million | -0.632x | -254.14% |
| 2018-06-30 | $20.62 Million | $-3.68 Million | -0.178x | +53.82% |
| 2017-06-30 | $6.13 Million | $-2.37 Million | -0.386x | +17.93% |
| 2016-06-30 | $820.48K | $-386.07K | -0.471x | +62.66% |
| 2015-06-30 | $1.28 Million | $-1.61 Million | -1.260x | -198.64% |
| 2014-06-30 | $1.52 Million | $-641.38K | -0.422x | -147.41% |
| 2013-06-30 | $-44.11K | $-39.26K | 0.890x | +101.38% |
| 2012-06-30 | $2.72K | $-174.62K | -64.269x | -2213.15% |
| 2011-06-30 | $202.29K | $-562.05K | -2.778x | -1806.55% |
| 2010-06-30 | $-1.20 Million | $-195.42K | 0.163x | +266.73% |
| 2009-06-30 | $-1.03 Million | $100.48K | -0.098x | -101.43% |
| 2008-06-30 | $-138.98K | $-951.15K | 6.844x | +366.18% |
| 2007-06-30 | $-950.42K | $-1.40 Million | 1.468x | +23.41% |
| 2006-06-30 | $-485.38K | $-577.40K | 1.190x | +13.61% |
| 2005-06-30 | $-670.63K | $-702.23K | 1.047x | -49.06% |
| 2004-06-30 | $-235.55K | $-484.19K | 2.056x | +158.86% |
| 2003-06-30 | $241.85K | $-844.62K | -3.492x | -293.57% |
| 2002-06-30 | $1.29 Million | $-1.14 Million | -0.887x | -686.17% |
| 2001-06-30 | $4.18 Million | $-471.69K | -0.113x | -- |
About InMed Pharmaceuticals Inc
InMed Pharmaceuticals Inc., a clinical stage pharmaceutical company, develops a pipeline of prescription-based products in the United States. The company operates through two segments, InMed Pharmaceuticals and BayMedica Commercial. The InMed Pharmaceuticals segment researches and develops cannabinoid-based pharmaceuticals products. The BayMedica Commercial segment develops proprietary manufactur… Read more